Fisher Scientific

The 2023 Maryland STEM Festival Holds its 2nd Parade in Frederick

Retrieved on: 
Wednesday, October 25, 2023
STEM, Horizon, Education, Verizon Communications, Video game, Life, Firaxis Games, Microsoft, State, AstraZeneca, Police, Conference, Organization, Fire, Multimedia, Morgan State University, Science, technology, engineering, and mathematics, Killing of Jeremy Mardis, Mathematics, Student, Mount Baker Park, Walking, School, Museum, Natural Resources, Esports, White–Turner–Sanford House, NASA, Frederick High School, Festival, Collection, Library, Fisher Scientific, Entertainment, Fireworks, Engineering, Science, Parade

FREDERICK, Md., Oct. 25, 2023 /PRNewswire-PRWeb/ -- The Maryland STEM Festival, Inc is hosting its second Parade in Downtown Frederick on November 4th. The Parade will start at 10 am from Frederick High School heading towards Baker Park. At Baker Park, there will be a diverse collection of booths with STEM oriented activities open until noon. Frederick Mayor O'Connor, County Executive Fitzwater, Councilman Young, State Senators Ken Kerr and Chris Few will be walking in the Parade. There will be vehicles from the Fire and Police Department and Department of Natural Resources in the Parade as well as the B360 Dirt Bike riders. Baker Park Booths will feature NASA, Zone Soccer, Fort Detrick, Fisher Scientific, the Frederick County Library, and more! Details about the parade are available here.

Key Points: 
  • The Maryland STEM Festival, Inc is hosting its second Parade in Downtown Frederick on November 4th.
  • FREDERICK, Md., Oct. 25, 2023 /PRNewswire-PRWeb/ -- The Maryland STEM Festival, Inc is hosting its second Parade in Downtown Frederick on November 4th.
  • The Maryland STEM Festival encourages all students, regardless of age, background, experience, or resources to learn more about and get involved with STEM.
  • Maryland STEM Festival, Inc. is a 501 (c) (3) corporation funded by generous support from companies, organizations, and individuals across Maryland.

Thermo Fisher Scientific Introduces New Chromosomal Microarray with Two-Day Turnaround Time to Increase Lab Productivity

Retrieved on: 
Tuesday, August 22, 2023
Research, Other Health, Pharmaceutical, Oncology, Medical Devices, Hospitals, Genetics, Clinical Trials, Science, Biotechnology, Medical Supplies, Health, Other Science, Pressure, DNA, Fisher Scientific, Centre for Applied Genomics, Thermo Fisher Scientific, Chas, Amniotic fluid, Data analysis, Genome, AIR, Blood, GCS, Saliva, Management, Medical imaging

Thermo Fisher Scientific, the world leader in serving science, today announced the launch of a new chromosomal microarray designed to improve cytogenetic research lab productivity, efficiency and profitability with an industry-leading two-day turnaround time.

Key Points: 
  • Thermo Fisher Scientific, the world leader in serving science, today announced the launch of a new chromosomal microarray designed to improve cytogenetic research lab productivity, efficiency and profitability with an industry-leading two-day turnaround time.
  • “Thermo Fisher Scientific is committed to innovation to meet the needs of our customers,” said Kevin Lowitz, vice president and general manager, microarray genetic solutions, Thermo Fisher Scientific.
  • As part of its commitment to enabling customers to advance cytogenetic research, Thermo Fisher has continued to update its instrumentation and services.
  • Thermo Fisher has also upgraded its high-performance microarray instrument for array processing, Applied Biosystems™ GeneChip™ System (GCS) 3000 , with the autoloader pre-assembled inside the scanner for more efficient installation and a modernized look.

Telesis Bio Secures Financing of $28.0 Million

Retrieved on: 
Wednesday, May 31, 2023
ACT, Molecular biology, AS, Health, Telesis, OR, Fisher Scientific, Doctor of Philosophy, Novalis, SELL, Syneos Health, Thermo Fisher Scientific, LAWS, Security (finance), Synthetic biology, Automation, Management, Pharmaceutical industry

SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in molecular biology automation solutions for multi-omic and synthetic biology applications, today announced it has signed a securities purchase agreement with a syndicate of healthcare-focused institutional investors that have agreed to provide initial upfront funding of $28.0 million in gross proceeds to Telesis Bio through a private placement of redeemable convertible preferred stock. The private placement also includes the issuance of warrants that, if cash exercised, would provide Telesis Bio with another $46.2 million in gross proceeds.

Key Points: 
  • The private placement also includes the issuance of warrants that, if cash exercised, would provide Telesis Bio with another $46.2 million in gross proceeds.
  • “We are pleased to announce this financing led by Novalis LifeSciences LLC with strong support from existing investors,” shared Todd R. Nelson, CEO and Founder of Telesis Bio.
  • “We now anticipate full year revenue for the company to be approximately $35 million and operating expenses, including non-cash and one-time charges to be approximately $55 million.
  • Gross margin expectations of approximately 57% remain unchanged.”
    The Company intends to use the proceeds from the financing for general corporate purposes.

Certara Announces the Completion of Arsenal Capital Partners’ Investment and the Appointment of David Spaight to the Board of Directors

Retrieved on: 
Thursday, December 8, 2022
Pharmacy, Drug discovery, PerkinElmer, MDS, Sale, Arsenal, Partnership, Fisher Scientific, WIL Research Laboratories, Investment, Charles River Laboratories, Pharmaceutical industry, Fine chemical, Certara

David Spaight, an Operating Partner at Arsenal, has been appointed to Certara’s Board of Directors, effective immediately.

Key Points: 
  • David Spaight, an Operating Partner at Arsenal, has been appointed to Certara’s Board of Directors, effective immediately.
  • Stephen McLean, a Senior Partner at Arsenal, will continue to serve on Certara’s Board of Directors.
  • “We are pleased with Arsenal’s continued support and confidence in Certara and welcome David Spaight to the Board of Directors,” said William F. Feehery, Chief Executive Officer of Certara.
  • Arsenal Capital Partners is a leading private equity firm that specializes in investments in industrial growth and healthcare companies.

Thermo Fisher Scientific’s Advanced Analytical Instruments Receive R&D 100 Awards

Retrieved on: 
Thursday, December 15, 2022
Manufacturing, Other Manufacturing, Science, Other Science, Machinery, Laboratory, Fisher Scientific, Thermo Fisher Scientific, Invitrogen, Peptide, PPD, Food, R, Mindful Scientific Inc., MAM, Drug discovery, Patient, Science, Mass spectrometry, Patheon, Research, Chromatography, West Pharmaceutical Services explosion, Applied Biosystems, Multimedia, Plasma protein binding, Health, Fine chemical, Renewable energy

Thermo Fisher Scientific Inc., the world leader in serving science, received R&D 100 Awards from R&D World Magazine for two of its most recently launched analytical instruments.

Key Points: 
  • Thermo Fisher Scientific Inc., the world leader in serving science, received R&D 100 Awards from R&D World Magazine for two of its most recently launched analytical instruments.
  • The R&D 100 Awards competition honors the latest innovations in science and technology, identifying the top 100 revolutionary technologies of the past year.
  • The Thermo Scientific Orbitrap Exploris MX Mass Detector was also a recipient of an R&D 100 Award in the Analytical/Test category .
  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion.

FDA Grants Emergency Use Authorization for Thermo Fisher Scientific’s Monkeypox Test

Retrieved on: 
Wednesday, December 14, 2022
Science, Other Science, Biotechnology, Pharmaceutical, Medical Supplies, Health, FDA, Infectious Diseases, Laboratory, Fisher Scientific, Thermo Fisher Scientific, Invitrogen, Severe acute respiratory syndrome coronavirus 2, PPD, Food, Mindful Scientific Inc., Monkeypox, Regulation of tobacco by the U.S. Food and Drug Administration, Infection, Patient, DNA, Science, Patheon, Research, PCR, Pharmaceutical Services Negotiating Committee, Polymerase chain reaction, FDA, Monkeypox virus, Applied Biosystems, COVID-19, Genetic, EUA, Health, Vaccine, Orthopoxvirus

Thermo Fisher Scientific, the world leader in serving science, today announced the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its Applied Biosystems TaqPath Monkeypox/Orthopox Virus DNA Kit, a polymerase chain reaction (PCR) test designed to detect non-variola Orthopoxviruses, including monkeypox virus, in approximately three-and-a-half hours.

Key Points: 
  • Thermo Fisher Scientific, the world leader in serving science, today announced the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its Applied Biosystems TaqPath Monkeypox/Orthopox Virus DNA Kit, a polymerase chain reaction (PCR) test designed to detect non-variola Orthopoxviruses, including monkeypox virus, in approximately three-and-a-half hours.
  • Ensuring that all U.S. laboratories have access to monkeypox PCR testing is a critical part of the response to this public health emergency, said Manoj Gandhi, senior medical director for Genetic Testing Solutions, Thermo Fisher Scientific.
  • In early 2020, Thermo Fisher was among the first companies to distribute an emergency use authorized assay to identify active SARS-CoV-2 infections with the TaqPath COVID-19 Combo Kit .
  • For Emergency Use Authorization Only; Rx Only
    Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion.

Nanomaterials Market Size, Share & Trends Analysis Report By Product, By Application, By Region And Segment Forecasts, 2022 - 2030

Retrieved on: 
Thursday, December 15, 2022
Laboratory, Biotechnology, Fisher Scientific, Iron, Carbon, Nanoparticle, Aerospace, University, R, Coating, Degenerative disease, Gold, Nickel, Nanotechnology, Nanomaterials, Toxicity, Aluminium, Research, 3D, Neurology, Investment, Government, Growth, Nanofiber, Electronics, USD, Fine chemical, Environmental remediation, Medical device, Aluminium oxide, Medicine, Silver, Automotive industry, Platinum, Copper, Titanium

View original content:https://www.prnewswire.com/news-releases/nanomaterials-market-size-share...

Key Points: 
  • Nanomaterials Market Size, Share & Trends Analysis Report By Product (Gold, Silver, Iron, Copper, Platinum, Titanium, Nickel, Aluminum Oxide), By Application (Aerospace, Automotive, Medical), By Region, And Segment Forecasts, 2022 - 2030
    The global nanomaterials market size is expected to reach USD 32.77 billion by 2030 and expand at a CAGR of 14.9% from 2022 to 2030.
  • In addition, nanotechnology is extensively used in the healthcare industry in various applications such as anti-infective, neurology, and cardiovascular disorders.
  • The titanium (Ti) nanomaterials product segment is expected to grow at a CAGR of 16.3% during the forecast period.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

FDA Grants De Novo Classification to HLA Typing Test for Use as a Companion Diagnostic with a T Cell Receptor Therapy for Metastatic or Unresectable Uveal Melanoma

Retrieved on: 
Wednesday, December 7, 2022
Research, FDA, Genetics, Health Technology, Biotechnology, Pharmaceutical, Health, Optical, Science, Oncology, Laboratory, Fisher Scientific, Thermo Fisher Scientific, Invitrogen, Survival, PPD, Mindful Scientific Inc., Immunotherapy, HLA, Protein, Patient, Science, Patheon, Research, Diversified Pharmaceutical Services, Disease, FDA, Classification, Applied Biosystems, Cell, The New England Journal of Medicine, Uveal melanoma, Eye, Health, SECORE, Vaccine, Medical imaging

The marketing authorization is the first of its kind, making the SeCore CDx HLA Sequencing System the only commercially available HLA typing companion diagnostic.

Key Points: 
  • The marketing authorization is the first of its kind, making the SeCore CDx HLA Sequencing System the only commercially available HLA typing companion diagnostic.
  • Cancer immunotherapies, including T cell receptor therapies, have been shown to prolong survival for patients with metastatic or unresectable tumors.
  • Because these proteins are expressed on nearly all nucleated cells in the body, high-resolution HLA typing is a critical step for patient identification.
  • KIMMTRAK, the first and only FDA-approved T cell receptor therapy for metastatic or unresectable uveal melanoma, is indicated for adults who are HLA-A*02:01 positive.

Thermo Fisher Scientific Raises Greenhouse Gas Emissions Reduction Target on Path to Net-zero Emissions

Retrieved on: 
Tuesday, December 6, 2022
Environmental Policy, Professional Services, Health, Environmental Issues, General Health, Environmental, Social and Governance (ESG), Other Science, Research, Environment, Science, Sustainability, Laboratory, Electricity, Fisher Scientific, Thermo Fisher Scientific, Invitrogen, TMO, PPD, Mindful Scientific Inc., Environment, Science, Targets, Paris Agreement, Wind, Patheon, Research, West Pharmaceutical Services explosion, NYSE, Investment, Paris, Applied Biosystems, Multimedia, Health, Renewable energy

This represents an important milestone in Thermo Fishers pursuit of a net-zero value chain by 2050 , which includes Scope 1, 2 and 3 emissions.

Key Points: 
  • This represents an important milestone in Thermo Fishers pursuit of a net-zero value chain by 2050 , which includes Scope 1, 2 and 3 emissions.
  • Our net-zero goal reflects Thermo Fishers commitment to environmental sustainability across the company, said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher.
  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion.
  • Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Thermo Fisher Scientific Launches TrueMark Infectious Disease Research Panels

Retrieved on: 
Tuesday, December 6, 2022
Technology, Manufacturing, Other Technology, Other Science, Other Manufacturing, Research, Science, Laboratory, Fisher Scientific, Thermo Fisher Scientific, Invitrogen, Infection, PPD, Mindful Scientific Inc., Workflow, Research, Science, TaqMan, Patheon, PCR, West Pharmaceutical Services explosion, Real-time, Real-time polymerase chain reaction, Applied Biosystems, Vertically transmitted infection, Genetic, MagMax, Genetic testing, Health, Vaccine

Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the TrueMark Infectious Disease Research Panels designed to enable rapid and accurate detection and categorization for investigating microorganisms that cause respiratory, vaginal, urinary, gastrointestinal, and sexually transmitted diseases.

Key Points: 
  • Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the TrueMark Infectious Disease Research Panels designed to enable rapid and accurate detection and categorization for investigating microorganisms that cause respiratory, vaginal, urinary, gastrointestinal, and sexually transmitted diseases.
  • TrueMark Infectious Disease Research Panels are analytically sensitive, real-time polymerase chain reaction (PCR) syndromic panels for the analysis of a wide range of infectious disease pathogens.
  • With the TrueMark Infectious Disease Research Panels, laboratories can choose either the readymade panels or create their own custom panels to suit their needs, said Dr. Manoj Gandhi, senior medical director of Genetic Testing Solutions at Thermo Fisher Scientific.
  • For more information on the TrueMark Infectious Disease Research Panels, please visit www.thermofisher.com/truemarkpluspanels .